Belgium Pharmaceutical - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The belgium pharmaceutical market size is expected to grow from USD 8.40 billion in 2025 to USD 8.89 billion in 2026 and is forecast to reach USD 11.78 billion by 2031 at 5.80% CAGR over 2026-2031. This report is Segmented by ATC/Therapeutic Class (Alimentary Tract & Metabolism, and More), Drug Type (Prescription [Branded and Generics] and OTC), Molecule Type (Small-Molecule, Biologics, Biosimilars, and ATMPs), and Distribution Channel (Hospital, Retail, and Online Pharmacies). Market Forecasts are Provided in Value (USD).

Belgium Pharmaceutical Market Trends and Insights

Rising Health Expenditure Per Capita

Belgium’s per-capita health spend reached USD 6,022, outperforming the EU-14 average and freeing budget space for high-cost biologics. Public pharmaceutical outlays are forecast to rise from 8% of GDP in 2022 to 8.9% by 2027, translating into a 36.6% nominal increase. The 2026 federal budget earmarked EUR 25 million for the Early and Equitable Fast Access program, cutting reimbursement timelines for oncology and rare-disease drugs. Industry payrolls of 44,738 direct staff plus 140,835 across the value chain amplify tax receipts and voter interest in sector stability. Retail drug spending per capita sits 6% below the EU mean, indicating untapped volume potential as the population ages and discretionary income grows.

High Burden of Chronic Diseases

Cancer and circulatory disorders still account for roughly half of national mortality, coupled with an 82.6-year life expectancy. Mature cardiovascular categories face generic erosion, yet the obesity-linked surge in GLP-1 demand offers a new growth arc. Dermatological biologics for psoriasis and atopic dermatitis are outpacing systemic corticosteroids, lifting the segment’s growth curve for 2026-2031. Belgium’s 16% obesity prevalence accelerates uptake of oral GLP-1 candidates such as orforglipron once Lilly’s EUR 2.6 billion Netherlands plant goes live in 2027. Persistent supply constraints through 2025 create latent demand that is unlocked by capacity additions.

Mandatory Post-Exclusivity Price Cuts

Belgium slashes originator prices by up to 38% once generic or biosimilar competition appears, compressing margin runways and discouraging smaller line extensions. The 2026 budget further trims hospital invoice reimbursement to 78% and imposes EUR 1-2 patient co-pays, squeezing value-chain profits. Managed Entry Agreements, worth EUR 1.6 billion in 2019 rebates, cap upside whenever sales overshoot negotiated ceilings. Protracted reimbursement reviews - 578 days on an EU average - plus reference pricing lower differentiation payoffs for formulation tweaks or adherence programs.

Other drivers and restraints analyzed in the detailed report include:

• Digital Prescription and E-Pharmacy Adoption
• EU Critical Medicines Act Supply Resilience Programs
• Hospital Financing Model Disincentivizing Biosimilar Uptake

Segment Analysis

Cardiovascular agents delivered 14.18% of the Belgium pharmaceutical market share in 2025 but confront generic-driven price ceilings as statins and ACE inhibitors mature. Dermatological products are projected to grow at a 7.54% CAGR through 2031, driven by monoclonal antibodies that offer superior remission rates in psoriasis and atopic dermatitis. Nervous-system drugs sustain volume via Belgium’s early adoption of disease-modifying therapies for multiple sclerosis and Alzheimer’s. Respiratory biologics that suppress IL-5 or IL-4/IL-13 pathways reduce exacerbations, while blood-forming agents face commoditization from direct oral anticoagulants. Insurance-backed fast-access funds tilt market mix in favor of oncology breakthroughs entering the residual “other” bucket.

Aging demographics and higher disposable incomes expand demand for osteoporosis, benign prostatic hyperplasia, and rheumatoid arthritis interventions. Patent filings totaling 417 in 2024 signal continued therapeutic diversification. GLP-1 therapies address metabolic conditions linked to the nation’s 16% obesity rate, with capacity expansion in neighboring the Netherlands set to clear supply bottlenecks beyond 2027. Belgium's pharmaceutical industry invests more in R&D toward immunology and rare diseases, fields with fewer entrenched generics.

Prescription lines represented 86.85% of total 2025 value, reinforcing Belgium pharmaceutical market size dominance in specialty areas such as oncology and neurology. Branded molecules endure post-exclusivity reductions yet command volume in protected niches, while generics leverage automatic substitution rules to serve primary-care staples. Over-the-counter remedies expand at 7.21% CAGR as consumers retain self-care habits formed during pandemic mobility curbs.

Digital prescription ubiquity gives online pharmacies a friction-less path to scale, although regulatory gates still block remote dispensing of Rx products. European harmonization efforts suggest broader e-dispensing rights within this decade. Managed Entry rebates ensure public budgets stay on-course even when specialty volumes grow, permitting a balanced mix of high-value prescriptions and value-priced generics.

Complete Report Scope:

• By ATC / Therapeutic Class
  • Alimentary Tract & Metabolism
  • Blood & Blood-Forming Organs
  • Cardiovascular System
  • Dermatologicals
  • Genito-Urinary System
  • Systemic Hormonal Preparations
  • Nervous System
  • Musculoskeletal System
  • Respiratory System
  • Other Therapeutic Classes
• By Drug Type
  • Prescription Drugs
    • Branded
    • Generics
  • OTC Drugs
• By Molecule Type
  • Small-Molecule Pharmaceuticals
  • Biologics
  • Biosimilars
  • Advanced Therapy Medicinal Products (ATMPs)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

List of Companies Covered in this Report:

• Abbvie
• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly and Company
• Roche
• GlaxoSmithKline
• Janssen Pharmaceutica NV (J&J)
• Merck
• Novartis
• Novo Nordisk
• Pfizer
• Sanofi
• Takeda Pharmaceutical Co.
• Teva Pharmaceutical Industries
• UCB
• Viatris
• Zentiva SA

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support